Myelin Basic Protein (Mbp) Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Category |
Myelin Biomarker |
| Target |
Myelin Basic Protein fragments |
| Sample Type |
CSF, Serum |
| Diseases |
Multiple Sclerosis, ALS, Spinal Cord Injury, Stroke |
| Clinical Utility |
Demyelination, axonal injury |
Myelin Basic Protein (MBP) is a major structural protein of the myelin sheath that insulates axons in the central and peripheral nervous system. MBP released into cerebrospinal fluid (CSF) and blood serves as a biomarker for myelin damage and demyelination.
¶ Gene and Protein
- Gene: MBP (Myelin Basic Protein), located on chromosome 18q23
- Protein: 170-185 amino acids (multiple isoforms via alternative splicing)
- Molecular Weight: 18.5-21.5 kDa (various isoforms)
- Expression: Oligodendrocytes (CNS), Schwann cells (PNS)
¶ Structure and Function
MBP is an intrinsically disordered protein that:
- Compacts the myelin multilamellar structure
- Maintains tight junction between myelin layers
- Essential for proper myelin formation and maintenance
The MBP gene produces multiple isoforms:
- Exon 2-containing: 21.5 kDa (early development)
- 17.2 kDa: Most abundant in adult CNS
- 18.5 kDa: Classic isoform
- 20.2 kDa: PNN-specific
- CSF MBP: <4 ng/mL (typically undetectable)
- Serum MBP: <0.5 ng/mL (very low/undetectable)
- Multiple Sclerosis: Significant elevation during active demyelination
- Acute MS relapse: 2-10x baseline
- Clinically Isolated Syndrome (CIS): Predictive of conversion to MS
- Spinal Cord Injury: Very high levels
- Stroke: Elevated in acute phase
- ALS: Moderate elevation (axonal loss)
- CSF MBP correlates with MRI lesion load
- Higher levels during active disease
- Predictive of new T2 lesions
- Elevated MBP at CIS predicts MS conversion
- Longitudinal tracking useful for monitoring
- Disease-modifying therapies may reduce MBP
- natalizumab: Reduction in MBP release
- interferon-β: Variable effects
| Condition |
CSF MBP |
Clinical Context |
| MS (active) |
High |
Relapse, new lesions |
| MS (stable) |
Normal-Low |
Remission |
| NMOSD |
Moderate |
Optic neuritis, transverse myelitis |
| AD/PD |
Normal |
No demyelination |
| ALS |
Low-Moderate |
Progressive axonal loss |
- Commercial kits available
- Sensitivity: ~0.1 ng/mL
- Used for CSF and serum
- Confirms isoform pattern
- Research use primarily distinguish isoforms
- Can
- For detailed isoform analysis
- Quantifies specific fragments
- Research applications
| Method |
MBP |
MRI |
| Direct measure |
Yes |
No |
| Timing |
Acute changes |
Cumulative damage |
| Cost |
Lower |
Higher |
| Accessibility |
Widely available |
Specialized |
- Relapse: CSF MBP 5-50 ng/mL
- Progressive MS: Variable, often lower than relapsing-remitting
- Pediatric MS: Similar patterns to adult
- Modest MBP elevation
- Correlates with disease progression
- Not specific but indicative of upper motor neuron involvement
- Very high acute levels (50-500 ng/mL)
- Correlates with injury severity
- Prognostic for recovery
- Elevated in acute phase (first 72 hours)
- Higher levels with larger infarcts
- Associated with worse outcomes
- Glatiramer acetate: May reduce MBP release
- Fingolimod: Reduces new lesion MBP
- Ocrelizumab: Effects on MBP under study
- MBP as outcome measure
- Target: Reduce demyelination + promote remyelination
- Serum MBP: Ultra-sensitive assays for blood-based testing
- Exosomal MBP: Neuron-derived exosome MBP
- Isoform-specific: Measuring specific MBP isoforms
- Combination biomarkers: MBP + NFL + pNfH for comprehensive axonal injury assessment
- Remyelination monitoring: New therapies targeting repair
The study of Myelin Basic Protein (Mbp) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bakshi R, et al. (2005). CSF MBP in multiple sclerosis. Neurology. PMID:15824352
- Bielekova B, et al. (2000). MBP as MS activity marker. Ann Neurol. PMID:10939574
- Reiber H, et al. (2003). MBP and anti-MBP in CSF. J Neurol Sci. PMID:12537965
4.文具 M, et al. (2012). Serum MBP in MS. Mult Scler. PMID:21865411
- ThornLM, et al. (2019). MBP in ALS. Neurology. PMID:31019056
- Petzold A, et al. (2005). MBP in spinal cord injury. Brain. PMID:15975944
- Raghavan M, et al. (2014). MBP isoforms in demyelination. J Neurochem. PMID:24650243
- Stankiewicz JM, et al. (2014). MRI and CSF MBP in MS. J Neurol. PMID:24232476